Humacyte, Inc. (HUMA)
(Delayed Data from NSDQ)
$2.28 USD
-0.12 (-5.00%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $2.27 -0.01 (-0.44%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Humacyte, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
HUMA 2.28 -0.12(-5.00%)
Will HUMA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for HUMA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HUMA
Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights
Humacyte, Inc. (HUMA) Stock Dips While Market Gains: Key Facts
HUMA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Humacyte, Inc. (HUMA) Stock Falls Amid Market Uptick: What Investors Need to Know
Humacyte, Inc. (HUMA) Dips More Than Broader Market: What You Should Know
Why Humacyte, Inc. (HUMA) Dipped More Than Broader Market Today
Other News for HUMA
Humacyte (HUMA) Maintains "Buy" Rating with $25 Price Target | HUMA Stock News
Humacyte (HUMA) Secures Symvess Sale to U.S. Military Treatment Facility | HUMA Stock News
Humacyte announces first sale of Symvess to U.S. Military Treatment Facility
Humacyte (HUMA) Shares Surge on First Symvess Sale to U.S. Military Facility